Gland Pharma jumps as USFDA concludes pre-approval inspection at Visakhapatnam facility

27 Feb 2025 Evaluate

Gland Pharma is currently trading at Rs. 1616.15, up by 20.65 points or 1.29% from its previous closing of Rs. 1595.50 on the BSE.

The scrip opened at Rs. 1604.85 and has touched a high and low of Rs. 1649.95 and Rs. 1587.10 respectively. So far 4578 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2220.95 on 06-Aug-2024 and a 52 week low of Rs. 1412.00 on 12-Feb-2025.

Last one week high and low of the scrip stood at Rs. 1649.95 and Rs. 1473.45 respectively. The current market cap of the company is Rs. 26989.63 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 39.84% and 8.33% respectively.

United States Food and Drug Administration (USFDA) has concluded Pre-approval inspection (PAI) for Sterile APIs at Gland Pharma’s facility at JNPC, Visakhapatnam. The inspection was conducted from February 19, 2025 to February 25, 2025.

The said inspection was concluded with three form 483 observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the USFDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity. 

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1413.00 -38.35 (-2.64%)
28-Apr-2025 15:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1841.45
Dr. Reddys Lab 1197.80
Cipla 1555.00
Lupin 2104.00
Zydus Lifesciences 886.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...